Biologics technology company WuXi Biologics (2269.HK) disclosed on Tuesday that its Drug Substance (DS) and Drug Product (DP) manufacturing facilities at Wuxi city has passed the US FDA seven-day surveillance inspection.
Under the US FDA's GMP regulations and surveillance, the three US FDA inspectors completed the inspection of the company's facilities for the production of Trogarzo, the first routine GMP inspection since product approval.
The US FDA conducts this inspection every two years upon product approval.The facilities passed the US FDA Pre-License Inspection in 2017, as well as the European Medicines Agency (EMA) Pre-Approval Inspection in March this year. It is the first and only Chinese biologics company to be approved by the US FDA, as well as EMA.
Under all three inspections, there are no issues related to data integrity, which demonstrates strong expertise in addressing this regulatory requirement, and the quality system at the company strictly adheres to the US FDA's GMP regulations.
Cereno Scientific's Phase IIb trial of CS1 in PAH approved by US FDA
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Mirum Pharmaceuticals to acquire Bluejay Therapeutics for HDV treatment
PureTech clears key FDA milestone for Phase 3 development of deupirfenidone
J & D Pharmaceuticals' investigational therapy for HCC receives US FDA Orphan Drug Designation
FDA lifts partial clinical hold on Vanda Pharmaceuticals' tradipitant for motion sickness
TransThera publishes clinical results from US-based Phase 2 trial of tinengotinib in CCA
Hope Medicine wins FDA Fast Track Designation for HMI-115 in endometriosis
MED-EL cochlear implant FDA approved for children 7 months and older